Dihydroartemisinin attenuates lipopolysaccharide-induced osteoclastogenesis and bone loss via the mitochondria-dependent apoptosis pathway

Abstract

Dihydroartemisinin (DHA) is a widely used antimalarial drug isolated from the plant Artemisia annua. Recent studies suggested that DHA has antitumor effects utilizing its reactive oxygen species (ROS) yielding mechanism. Here, we reported that DHA is inhibitory on lipopolysaccharide (LPS)-induced osteoclast (OC) differentiation, fusion and bone-resorption activity in vitro. Intracellular ROS detection revealed that DHA could remarkably increase ROS accumulation during LPS-induced osteoclastogenesis. Moreover, cell apoptosis was also increased by DHA treatment. We found that DHA-activated caspase-3 increased Bax/Bcl-2 ratio during LPS-induced osteoclastogenesis. Meanwhile, the translocation of apoptotic inducing factor (AIF) and the release of cytochrome c from the mitochondria into the cytosol were observed, indicating that ROS-mediated mitochondrial dysfunction is crucial in DHA-induced apoptosis during LPS-induced osteoclastogenesis. In vivo study showed that DHA treatment decreased OC number, prevents bone loss, rescues bone microarchitecture and restores bone strength in LPS-induced bone-loss mouse model. Together, our findings indicate that DHA is protective against LPS-induced bone loss through apoptosis induction of osteoclasts via ROS accumulation and the mitochondria-dependent apoptosis pathway. Therefore, DHA may be considered as a new therapeutic candidate for treating inflammatory bone loss.

Graphene‐Based MicroRNA Transfection Blocks Preosteoclast Fusion to Increase Bone Formation and Vascularization

“…We evaluated the in vivo therapeutic effects of GO‐PEI‐miR‐7b in osteoporotic OVX mice model as previously reported 24. GO‐PEI‐miR‐7b was injected intraperitoneally three times a week for four weeks.…”

Interleukin‐37 inhibits osteoclastogenesis and alleviates inflammatory bone destruction

“…For the micro‐computed tomography (micro‐CT) analysis, the femur tissues were scanned with viva CT 40 instrument (Scanco Medical, Brüttisellen, Switzerland) and the bone volume per tissue volume was calculated as described in a previous study (Dou et al, ). The scan of the trabecular bone was performed from the growth plate.…”

Physalin D inhibits RANKL-induced osteoclastogenesis and bone loss via regulating calcium signaling

“…Detailed procedures were described in a previous study (26). For bone resorption pit-formation tests, cells were incubated in 48-well plates covered with bovine bone slices of 1 × 10 4 cells/well, as described previously (27). In brief, cells were induced with RANKL (100 ng/ml) and M-CSF (50 ng/ml) for 3 days.…”